title: Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin.
abstract: Two cases of autoimmune hemolytic anemia that occurred during the treatment of chronic hepatitis C with pegylated alpha-2a interferon and ribavirin, in HIV coinfected patients, are presented and described. The late occurrence (after six months of therapy) of this severe hemolytic anemia leads to the recommendation that hemoglobin levels should be monitored throughout the treatment period, even among patients who presented stable hemoglobin levels in the preceding months.
authors.affiliation: Division of Infectious and Tropical Diseases, Department of Internal Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP.
authors.forename: Fernando Crivelenti
authors.initials: FC
authors.lastname: Vilar
authors.forename: Gleusa de
authors.initials: Gd
authors.lastname: Castro
authors.forename: Maria Janete
authors.initials: MJ
authors.lastname: Moya
authors.forename: Ana de Lourdes Candolo
authors.initials: Ade L
authors.lastname: Martinelli
authors.forename: Gil Cunha
authors.initials: GC
authors.lastname: De Santis
authors.forename: Ana Paula Costa Nunes da Cunha
authors.initials: AP
authors.lastname: Cozac
authors.forename: José Fernando de Castro
authors.initials: JF
authors.lastname: Figueiredo
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced* / Q000175:diagnosis; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin